NZ311319A - The treatment of HIV and other viral infections using the peptide DP-178 or DP-107 in combination therapy - Google Patents

The treatment of HIV and other viral infections using the peptide DP-178 or DP-107 in combination therapy

Info

Publication number
NZ311319A
NZ311319A NZ311319A NZ31131996A NZ311319A NZ 311319 A NZ311319 A NZ 311319A NZ 311319 A NZ311319 A NZ 311319A NZ 31131996 A NZ31131996 A NZ 31131996A NZ 311319 A NZ311319 A NZ 311319A
Authority
NZ
New Zealand
Prior art keywords
hiv
antiviral
treatment
viral infections
peptide
Prior art date
Application number
NZ311319A
Other languages
English (en)
Inventor
Ross M Johnson
Dennis M Lambert
Original Assignee
Trimeris Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trimeris Inc filed Critical Trimeris Inc
Publication of NZ311319A publication Critical patent/NZ311319A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ311319A 1995-06-07 1996-06-06 The treatment of HIV and other viral infections using the peptide DP-178 or DP-107 in combination therapy NZ311319A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48195795A 1995-06-07 1995-06-07
PCT/US1996/009499 WO1996040191A1 (en) 1995-06-07 1996-06-06 The treatment of hiv and other viral infections using combinatory therapy

Publications (1)

Publication Number Publication Date
NZ311319A true NZ311319A (en) 2000-01-28

Family

ID=23914065

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ311319A NZ311319A (en) 1995-06-07 1996-06-06 The treatment of HIV and other viral infections using the peptide DP-178 or DP-107 in combination therapy

Country Status (10)

Country Link
US (2) US6475491B1 (https=)
EP (1) EP0831873A4 (https=)
JP (1) JPH11507632A (https=)
KR (1) KR100571215B1 (https=)
CN (1) CN1192688A (https=)
AU (1) AU723537B2 (https=)
BR (1) BR9609152A (https=)
CA (1) CA2224008C (https=)
NZ (1) NZ311319A (https=)
WO (1) WO1996040191A1 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6271198B1 (en) 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
US6841657B2 (en) 1997-04-17 2005-01-11 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6818740B1 (en) 1997-04-17 2004-11-16 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6150088A (en) 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
US7960504B2 (en) 1998-07-30 2011-06-14 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6747126B1 (en) 1998-07-30 2004-06-08 Whitehead Institute For Biomedical Research Peptide inhibitors of HIV entry
AU4988900A (en) 1999-05-05 2000-11-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The T20/dp178 and t21/dp107 are activators of human phagocyte formyl peptide receptors
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
CA2395291C (en) 1999-12-16 2012-09-11 Whitehead Institute For Biomedical Research Five-helix protein
US6605427B2 (en) 2000-02-10 2003-08-12 Panacos Pharmaceuticals, Inc. Assay for detection of viral fusion inhibitors
CA2403718A1 (en) * 2000-03-17 2001-09-27 Panacos Pharmaceuticals, Inc. A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of hiv envelope proteins
US20050065319A1 (en) * 2000-12-19 2005-03-24 Baroudy Bahige M. Combination method for treating viral infections
KR100614714B1 (ko) 2001-06-15 2006-08-21 에프. 호프만-라 로슈 아게 ｇｐ41 단편의 아세틸화
AU2003210659A1 (en) * 2002-01-24 2003-09-02 Sangstat Medical Corporation Combination therapy for treatment of hiv infection
EP1542718B1 (en) 2002-09-24 2015-11-11 Dong Xie Peptide derivative fusion inhibitors of hiv infection
US7556813B2 (en) * 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
AU2003299085B2 (en) * 2002-09-27 2008-04-10 Tanox, Inc. Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome
DK1583542T3 (da) 2003-01-14 2008-09-22 Gilead Sciences Inc Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
WO2004108885A2 (en) * 2003-05-06 2004-12-16 Syntonix Pharmaceuticals, Inc. Fc chimeric proteins with anti-hiv drugs
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
PL2298347T3 (pl) * 2003-05-06 2016-03-31 Bioverativ Therapeutics Inc Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
AU2004238263A1 (en) * 2003-05-06 2004-11-25 Syntonix Pharmaceuticals, Inc. Inhibition of drug binding to serum albumin
WO2005060350A2 (en) * 2003-12-22 2005-07-07 Yeda Research & Development Co. Ltd. Diastereomeric peptides useful as inhibitors of membrane protein assembly
AU2004313242A1 (en) * 2004-01-07 2005-07-28 Trimeris, Inc. HIV gp41 HR2-derived synthetic peptides, and their use in therapy to inhibit transmission of human immunodeficiency virus
JP5069558B2 (ja) 2004-06-01 2012-11-07 メルク・シャープ・エンド・ドーム・コーポレイション ＨＩＶｇｐ４１融合中間物質の安定したペプチド模倣薬
US20060154895A1 (en) * 2004-12-09 2006-07-13 Maxwell Gordon Method of treating acquired immunedeficiency syndrome
GB0501352D0 (en) * 2005-01-21 2005-03-02 Slingsby Jason H Use of glycosylation modulators in combination with membrane fusion inhibitors for treatment of infections caused by viruses bearing glycosylated envelope
EP1868652A2 (en) * 2005-04-05 2007-12-26 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Method for shielding functional sites or epitopes on proteins
TWI341844B (en) 2006-02-02 2011-05-11 Trimeris Inc Hiv fusion inhibitor peptides with improved biological properties
EP1886696A1 (en) * 2006-08-03 2008-02-13 Endotis Pharma Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins
EP2054086A1 (en) 2006-08-17 2009-05-06 F. Hoffmann-Roche AG A conjugate of an antibody against ccr5 and an antifusogenic peptide
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
MX2009006398A (es) 2006-12-12 2009-06-23 Biorexis Pharmaceutical Corp Genotecas de proteinas de fusion de transferrina.
US20090143288A1 (en) * 2007-03-13 2009-06-04 Roche Palo Alto Llc Peptide-complement conjugates
CA2682848A1 (en) * 2007-04-03 2008-10-16 Trimeris, Inc. Novel formulations for delivery of antiviral peptide therapeutics
CL2008002092A1 (es) 2007-07-20 2009-05-29 Hoffmann La Roche Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
CN101874038A (zh) * 2007-09-25 2010-10-27 特里梅里斯公司 治疗性抗-hiv肽的合成方法
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
MX2013002556A (es) 2010-09-14 2013-05-28 Hoffmann La Roche Polipeptido de fusion de dedo de serpina.
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
CN103974971B (zh) * 2012-02-28 2016-09-14 中国人民解放军军事医学科学院毒物药物研究所 用于抑制hiv的多肽、其药物组合物及其用途
WO2014145718A2 (en) 2013-03-15 2014-09-18 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
EP3478324A1 (en) 2016-07-01 2019-05-08 GlaxoSmithKline Intellectual Property (No.2) Limited Antibody-drug conjugates and therapeutic methods using the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141867A (en) * 1987-02-02 1992-08-25 E. I. Du Pont De Nemours And Company Nucleotide sequence encoding a human immunodeficiency virus antigen
US4950652A (en) * 1987-03-23 1990-08-21 Hem Research, Inc. dsRNAs for combination therapy in the treatment of viral diseases
US5077280A (en) 1988-04-12 1991-12-31 Brown University Research Foundation Treatment of viral infections
GB8815241D0 (en) 1988-06-27 1988-08-03 Wellcome Found Antiviral combinations & compounds therefor
WO1990007119A1 (en) 1988-12-20 1990-06-28 Immunodiagnostics, Inc. Synthetic hiv-like peptides, their compositions and uses
US6248574B1 (en) 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
IL102092A (en) 1991-06-11 1996-11-14 Microgenesys Inc Use of recombinant hiv envelope protein in medicament for treating hiv and therapeutic composition containing the agglomerated protein
KR100358209B1 (ko) * 1992-07-20 2003-01-24 듀크 유니버시티 Hiv복제를저해하는조성물
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities

Also Published As

Publication number Publication date
KR100571215B1 (ko) 2006-10-24
US6475491B1 (en) 2002-11-05
WO1996040191A1 (en) 1996-12-19
MX9709682A (es) 1998-06-30
AU723537B2 (en) 2000-08-31
EP0831873A4 (en) 2002-07-17
KR19990022685A (ko) 1999-03-25
CA2224008C (en) 2009-08-18
US6861059B2 (en) 2005-03-01
JPH11507632A (ja) 1999-07-06
BR9609152A (pt) 1999-05-04
US20030103998A1 (en) 2003-06-05
CA2224008A1 (en) 1996-12-19
CN1192688A (zh) 1998-09-09
AU6261996A (en) 1996-12-30
EP0831873A1 (en) 1998-04-01

Similar Documents

Publication Publication Date Title
NZ311319A (en) The treatment of HIV and other viral infections using the peptide DP-178 or DP-107 in combination therapy
UA29429C2 (uk) Фармацевтична композиція для лікування вірусних інфекцій, спосіб отримання композиції, спосіб лікування або профілактики віл-інфекції у людини
BG102984A (en) Device for the treatment of herpes simplex virus and other infections diseases
RO115700B1 (ro) Metodă de tratament cu interferon
IL134345A0 (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
AU3698697A (en) Method for preserving infectious recombinant viruses, aqueous viral suspension and use as medicament
IL109644A0 (en) Viral vectors and their use in gene therapy
FI955154A0 (fi) Viruskombinantteja ja niiden käyttö geeniterapiassa
HK1043311A1 (zh) 使用替代-1,5-二脱氧-1,5-亚氨基-d-glucitol化合物治疗肝炎病毒感染
NZ332720A (en) Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
GR3024699T3 (en) Use of dideoxy nucleoside analogues in the treatment of viral infections.
DK0663835T3 (da) Anvendelse af parathormon, dets biologisk aktive fragmenter og relaterede peptider til behandling af graviditet
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
IL121272A (en) Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
MY105855A (en) Therapeutic nucleotides.
AU5158000A (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
CA2285463A1 (en) A combination therapy for hiv infections
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
AU4312093A (en) Use of a hymenoptera venom for the manufacture of a medicament for treating dna virus infections
WO2000078800A3 (en) Combined decorin binding protein and outer surface protein compositions and methods of use
AU5155700A (en) Gene therapy of pulmonary disease
MY111746A (en) Therapeutic nucleosides.
AU2396900A (en) Treatment and prevention of hiv and other viral infections
BR9812466A (pt) Uso de ifn-alfa e amantadina para o tratamento da hepatite c crÈnica

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired